Reduced YAP1 and FOLR1 in gliomas predict better response to chemotherapeutics

• Published in: Cellular signalling Vol. 109; p. 110738
• Main Authors: Patrick, Shruti, Lathoria, Kirti, Suri, Vaishali, Sen, Ellora
• Format: Journal Article
• Language: English
• Published: England Elsevier Inc 01.09.2023
• Subjects: DNA damage; FOLR1; Glioma; IDH1 mutation; Immune response; YAP1; YAP1; H2AX; SLC46A1; CXCL8; DNA damage; SHMT1; TYMS; SASP; RFC; IDH1 mutation; DDR; GBM; FBP; SLC19A1; Immune response; PCFT; MGMT; IDH1; 2-HG; LGG; TCGA; DHFR; IL6; TEAD; Glioma; IL8; ATM; FOLR1; GAPDH

Gliomas harbouring mutations in IDH1 (isocitrate dehydrogenase 1) are characterized by greater sensitivity to chemotherapeutics. These mutants also exhibit diminished levels of transcriptional coactivator YAP1 (yes-associated protein 1). Enhanced DNA damage in IDH1 mutant cells, as evidenced by γH2A...